These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 11178124)

  • 1. Anti-cytokine therapy in chronic destructive arthritis.
    van den Berg WB
    Arthritis Res; 2001; 3(1):18-26. PubMed ID: 11178124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a rationale for combined TNF and IL-1 blocking in arthritis?
    van den Berg WB
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S21-5. PubMed ID: 14989425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg.
    Brennan FM
    Arthritis Res; 2001; 3(4):211-3; discussion 214-5. PubMed ID: 11438037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arguments for interleukin 1 as a target in chronic arthritis.
    van den Berg WB
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i81-4. PubMed ID: 11053095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.
    Koenders MI; Joosten LA; van den Berg WB
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii29-33. PubMed ID: 17038468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra.
    Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
    Arthritis Rheum; 1996 May; 39(5):797-809. PubMed ID: 8639177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
    Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
    J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint inflammation and cartilage destruction may occur uncoupled.
    van den Berg WB
    Springer Semin Immunopathol; 1998; 20(1-2):149-64. PubMed ID: 9836374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases.
    Möller B; Villiger PM
    Springer Semin Immunopathol; 2006 Jun; 27(4):391-408. PubMed ID: 16738952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
    Maini RN; Elliott MJ; Brennan FM; Williams RO; Chu CQ; Paleolog E; Charles PJ; Taylor PC; Feldmann M
    Immunol Rev; 1995 Apr; 144():195-223. PubMed ID: 7590814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of different types of moxibustion intervention on expression of inflammatory cytokines IL-1 and TNF-alpha in rabbits with rheumatoid arthritis].
    Yang HQ; Liu XG; Yang X; Chen T; Yu SG
    Zhen Ci Yan Jiu; 2013 Apr; 38(2):134-9. PubMed ID: 23819216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal antibody therapy for rheumatoid arthritis].
    Ishii T; Saeki Y
    Nihon Rinsho; 2002 Mar; 60(3):551-5. PubMed ID: 11904972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro- and anti-inflammatory cytokines in rheumatoid arthritis.
    Isomäki P; Punnonen J
    Ann Med; 1997 Dec; 29(6):499-507. PubMed ID: 9562516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I.
    van den Berg WB; Bresnihan B
    Baillieres Best Pract Res Clin Rheumatol; 1999 Dec; 13(4):577-97. PubMed ID: 10652641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis.
    Kay J; Calabrese L
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii2-iii9. PubMed ID: 15150426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting TNF alpha for the therapy of rheumatoid arthritis.
    Maini RN; Elliott M; Brennan FM; Williams RO; Feldmann M
    Clin Exp Rheumatol; 1994; 12 Suppl 11():S63-6. PubMed ID: 7768056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.
    Butler DM; Maini RN; Feldmann M; Brennan FM
    Eur Cytokine Netw; 1995; 6(4):225-30. PubMed ID: 8789287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF alpha and IL-1 beta are separate targets in chronic arthritis.
    van den Berg WB; Joosten LA; van de Loo FA
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S105-14. PubMed ID: 10589368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
    Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
    Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.